BrightSpring Health Services, Inc. vs PACS Group, Inc., two Medical Care stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
7.22 against 2.71 is the figure pair that decides this page: free-cash yield, the skilled-nursing operator PACS handing back nearly triple what roll-up BrightSpring does, while also carrying a fifth of the leverage, 0.24 turns against 1.29. The multiples run the other way, 49.1 times for BrightSpring's acquisition-fueled growth against 27 for PACS, whose 23.4% return on equity is the better operating number besides. Margins are care-services thin at both, 3.4% and 8.5% operating. Two ways to own government-reimbursed care: pay double the multiple for growth on borrowed money, or half for cash flow with a dividend attached. The market has picked its favorite and the fundamentals quietly disagree.
Comparison updated 2026-07-10.
| Metric | BTSG | PACS |
|---|---|---|
| Price | $68.80 | $41.88 |
| Market cap | $15.2B | $6.8B |
| Sector | Medical Care | Medical Care |
| Stage | Growth | Growth |
| Implied growth (priced in) | — | +7.9% |
| P/E | 49.1 | 27.0 |
| P/B | 7.69 | 6.51 |
| P/S | 1.12 | 1.25 |
| EV/EBITDA | 41.7 | 17.8 |
| Revenue growth | +28.0% | +23.6% |
| Gross margin | 13.3% | — |
| Operating margin | 3.4% | 8.4% |
| Net margin | 2.3% | 4.5% |
| Return on equity | 15.7% | 23.4% |
| Return on assets | 5.0% | 4.3% |
| Return on invested capital | 7.2% | 21.0% |
| FCF yield | 2.7% | 7.2% |
| Dividend yield | — | 0.5% |
| Debt / equity | 1.29 | 0.24 |
| Current ratio | 1.74 | 0.99 |
| Altman Z (solvency) | 4.65 | 2.01 |
| Piotroski F (quality) | 5 / 9 | 7 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.